These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34561409)

  • 1. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
    Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
    J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
    Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
    Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
    Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
    Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
    Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer.
    Gilbert A; Williams C; Azuero A; Burkard ME; Kenzik K; Garrett-Mayer E; Meersman S; Rocque G
    Clin Breast Cancer; 2021 Aug; 21(4):292-301. PubMed ID: 33309481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
    Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
    Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
    den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
    Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Difference in Prognostic Outcomes Between
    Yamamura J; Kamigaki S; Fujita J; Osato H; Komoike Y
    In Vivo; 2018; 32(2):353-358. PubMed ID: 29475920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer.
    Brufsky A; Kwan ML; Sandin R; Stergiopoulos S; Karanth S; Cha-Silva AS; Makari D; Goyal RK
    Breast Cancer Res Treat; 2024 Nov; 208(2):223-235. PubMed ID: 39177933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
    Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R; Nottage M; Collins IM; Torres J; Lombard J; Johns J; Harold M; Malik L
    Breast Cancer Res Treat; 2020 Nov; 184(1):87-95. PubMed ID: 32779037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.
    File DM; Pascual T; Deal AM; Wheless A; Perou CM; Claire Dees E; Carey LA
    Breast Cancer Res Treat; 2022 Nov; 196(1):153-162. PubMed ID: 36008651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
    BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics.
    Hao Y; Meyer N; Song X; Shi N; Johnson W; Juneau P; Yardley DA; Willemann Rogerio J
    Curr Med Res Opin; 2015 Feb; 31(2):275-88. PubMed ID: 25365467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
    Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
    Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.
    Epaillard N; Lusque A; Jacot W; Mailliez A; Bachelot T; Arnedos M; Le Du F; Brain E; Ferrero JM; Massard V; Desmoulins I; Mouret-Reynier MA; Levy C; Gonçalves A; Leheurteur M; Petit T; Filleron T; Bosquet L; Pistilli B; Frenel JS
    ESMO Open; 2024 May; 9(5):103447. PubMed ID: 38703431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use and results of systemic treatments for de novo and recurrent metastatic breast cancer: a population-based cohort study.
    Lao C; Kuper-Hommel M; Campbell I; Elwood M; Lawrenson R
    N Z Med J; 2021 Nov; 134(1545):47-59. PubMed ID: 34788271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.
    Tao L; Chu L; Wang LI; Moy L; Brammer M; Song C; Green M; Kurian AW; Gomez SL; Clarke CA
    Cancer Causes Control; 2016 Sep; 27(9):1127-38. PubMed ID: 27496200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of neutrophil-to-lymphocyte ratio in
    Shao B; Li H; Liu X; Song G; Jiang H; Yan Y; Zhang R; Ran R; Zhang J; Liu Y; Wang H; Wang J; Di L
    Ann Transl Med; 2023 Jan; 11(2):45. PubMed ID: 36819544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.